Skip to main content
. 2024 Feb 20;6(3):86–93. doi: 10.1253/circrep.CR-23-0098

Table 3.

Clinical Outcomes at 1 Year by Country/Region

Outcomes at 1 year, n
(annual incidence, %) [95% CI]
Total
(N=3,359)
South Korea
(n=1,887)
Taiwan
(n=983)
Hong Kong
(n=190)
Thailand
(n=299)
P value*
All-cause death 58 (1.78)
[1.38; 2.31]
16 (0.87)
[0.54; 1.43]
21 (2.19)
[1.43; 3.36]
10 (5.45)
[2.93; 10.12]
11 (3.90)
[2.16; 7.03]
<0.0001*
CV death 22 (0.68)
[0.45; 1.03]
9 (0.49)
[0.26; 0.94]
6 (0.63)
[0.28; 1.39]
3 (1.63)
[0.53; 5.07]
4 (1.42)
[0.53; 3.77]
0.2
Hemorrhagic stroke 9 (0.28)
[0.14; 0.53]
5 (0.27)
[0.11; 0.66]
2 (0.21)
[0.05; 0.84]
2 (1.09)
[0.27; 4.38]
0
[0.00; NE]
0.3
Ischemic stroke 37 (1.14)
[0.83; 1.58]
17 (0.93)
[0.58; 1.50]
11 (1.16)
[0.64; 2.09]
1 (0.55)
[0.08; 3.88]
8 (2.85)
[1.43; 5.70]
0.06
SEEs 1 (0.03)
[0.00; 0.22]
0
[0.00; NE]
0
[0.00; NE]
0
[0.00; NE]
1 (0.36)
[0.05; 2.52]
1.0
Major bleeding (ISTH) 43 (1.33)
[0.99; 1.79]
18 (0.99)
[0.62; 1.57]
13 (1.37)
[0.79; 2.35]
7 (3.88)
[1.85; 8.14]
5 (1.78)
[0.74; 4.29]
0.02*
 Major GI bleeding 18 (0.55)
[0.35; 0.88]
5 (0.27)
[0.11; 0.66]
5 (0.52)
[0.22; 1.26]
3 (1.64)
[0.53; 5.10]
5 (1.78)
[0.74; 4.29]
0.01*
 Intracranial hemorrhage 12 (0.37)
[0.21; 0.65]
5 (0.27)
[0.11; 0.66]
4 (0.42)
[0.16; 1.11]
3 (1.65)
[0.53; 5.12]
0
[0.00; NE]
0.1
Major or CRNM bleeding 70 (2.18)
[1.72; 2.75]
26 (1.43)
[0.97; 2.10]
23 (2.44)
[1.62; 3.66]
11 (6.23)
[3.45; 11.24]
10 (3.60)
[1.94; 6.69]
0.0004*
Net clinical outcome 132 (4.11)
[3.47; 4.88]
50 (2.77)
[2.10; 3.65]
44 (4.66)
[3.46; 6.26]
15 (8.34)
[5.03; 13.84]
23 (8.29)
[5.51; 12.47]
<0.0001*

*Significant P values indicate a significant effect of the region (based on Wald test). All strokes, SEEs, myocardial infarctions, major bleeding (ISTH), and all-cause death. CI, confidence interval; CRNM, clinically relevant nonmajor; CV, cardiovascular; GI, gastrointestinal; ISTH, International Society on Thrombosis and Haemostasis; NE, not estimable; SEE, systemic embolic event.